Filtered By:
Condition: Bleeding
Education: Academia

This page shows you your search results in order of date. This is page number 11.

Order by Relevance | Date

Total 422 results found since Jan 2013.

Prasugrel-based De-Escalation of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With STEMI
CONCLUSIONS: Prasugrel dose de-escalation reduced the rate of NACE and bleeding, without increasing the rate of ischemic events in NSTE-ACS patients but not in STEMI patients.PMID:35129316 | DOI:10.4070/kcj.2021.0293
Source: Korean Circulation Journal - February 7, 2022 Category: Cardiology Authors: You-Jeong Ki Bong Ki Lee Kyung Woo Park Jang-Whan Bae Doyeon Hwang Jeehoon Kang Jung-Kyu Han Han-Mo Yang Hyun-Jae Kang Bon-Kwon Koo Dong-Bin Kim In-Ho Chae Keon-Woong Moon Hyun Woong Park Ki-Bum Won Dong Woon Jeon Kyoo-Rok Han Si Wan Choi Jae Kean Ryu Myu Source Type: research

Comparison of Net Clinical Benefit Between Clopidogrel and Ticagrelor Following Percutaneous Coronary Intervention in Patients in China With Acute Coronary Syndrome
CONCLUSION: In Chinese ACS patients who underwent PCI with second-generation DESs, outpatient use of clopidogrel dual antiplatelet therapy (DAPT) was associated with reduction in NACCE and bleeding.PMID:34904209 | DOI:10.1007/s12325-021-01907-3
Source: Adv Data - December 14, 2021 Category: Epidemiology Authors: Dandan Li Yang Sun Xiaoran Ye Lanting Li Yundai Chen Daowen Wang Source Type: research

White blood cell count and clinical outcomes after left main coronary artery revascularization: insights from the EXCEL trial
Conclusion There was no association between baseline WBCc and 30-day or 5-year clinical outcomes after PCI or CABG. The absence of a clear incremental increase in events with increasing WBCc in the current analysis indicates that WBCc should not routinely be used as a prognostic marker or to guide revascularization decisions in patients with LMCAD.
Source: Coronary Artery Disease - December 9, 2021 Category: Cardiology Tags: PCI Source Type: research

Comparison of Prasugrel and Ticagrelor for Patients with Acute Coronary Syndrome: A Systematic Review and Meta-analysis
Conclusion: Compared with prasugrel, ticagrelor did not reduce the primary composite endpoint of MI, stroke and cardiovascular death at a weighted mean follow up of 11 months. There was no significant difference between the secondary outcomes exce pt myocardial infarction.
Source: Cardiology - November 5, 2021 Category: Cardiology Source Type: research

Clinical Outcomes of Ticagrelor in Korean Patients with Acute Myocardial Infarction without High Bleeding Risk
CONCLUSIONS: The bleeding risk of ticagrelor was attenuated in Korean patients with AMI without HBR. Appropriate patient selection could reduce in-hospital bleeding complications associated with ticagrelor in Korean patients with AMI who underwent successful PCI.PMID:34725976 | DOI:10.3346/jkms.2021.36.e268
Source: J Korean Med Sci - November 2, 2021 Category: General Medicine Authors: Keun-Ho Park Myung Ho Jeong Hyun Kuk Kim Young-Jae Ki Sung Soo Kim Dong-Hyun Choi Young-Youp Koh Youngkeun Ahn Hyo-Soo Kim Hyeon-Cheol Gwon Seung-Woon Rha Jin-Yong Hwang KAMIR-NIH registry investigators Source Type: research